Tyro3介导肿瘤细胞与微环境浸润中性粒细胞串话促进宫颈癌放疗抵抗的机制研究
批准号:
82102850
项目类别:
青年科学基金项目(C类)
资助金额:
30.0 万元
负责人:
朱晨静
依托单位:
学科分类:
肿瘤物理治疗
结题年份:
2024
批准年份:
2021
项目状态:
已结题
项目参与者:
朱晨静
中文摘要
放疗抵抗是影响宫颈癌远期疗效的主要因素之一,机制仍不清楚。前期通过810例泛癌组织芯片筛选发现受体酪氨酸激酶Tyro3主要高表达于宫颈癌,并在根治性放疗患者中表达越高、预后越差;宫颈癌小鼠模型中Tyro3高表达增加放疗抵抗性;Tyro3表达与微环境中性粒细胞(TAN)浸润正相关。机制初探提示Tyro3可能促进肿瘤释放CCL3趋化微环境TAN、TAN反馈激活肿瘤MAPK通路诱导宫颈癌放疗抵抗。据此提出“高表达Tyro3可通过释放CCL3介导肿瘤细胞与微环境TAN之间正反馈串话,进而诱导宫颈癌放疗抵抗”的科学假说。项目拟通过体内外实验明确Tyro3诱导宫颈癌放疗抵抗的功能,采用共培养体系及小鼠模型、设计拯救实验阐明Tyro3与TAN串话介导放疗抵抗的机制,最后临床大样本验证Tyro3/TAN/MAPK反馈环与宫颈癌放疗抵抗的相关性。本研究的成功实施,将为逆转宫颈癌放疗抵抗提供新理论和新靶点。
英文摘要
Radioresistance is one of the main factors affecting the long-term curative effect of cervical cancer, and the mechanism is still unclear. Previously through 810 cases of pan-cancer tissue array screening, we found that the receptor tyrosine kinase Tyro3 was mainly expressed in cervical cancer, and the higher the expression in patients receiving radical radiotherapy, the worse the prognosis. High expression of Tyro3 in cervical cancer mice model increased the resistance to radiotherapy. Moreover, Tyro3 expression was positively related to the infiltration of tumor-associated neutrophils (TAN). Preliminary exploration of mechanism suggested that Tyro3 might promote the release of CCL3 that led to the chemotaxis of TAN, which in turn activated MAPK signaling pathway in tumor cells to induce radioresistance of cervical cancer. Therefore, we speculated that "high expression of Tyro3 could induce a positive feedback crosstalk between tumor cells and TAN, thus inducing radioresistance of cervical cancer". We intend to clarify the function of Tyro3 in inducing radioresistance through in vitro and in vivo experiments, and explain the mechanism of the crosstalk between Tyro3 and TAN in mediating radioresistance using co-culture system, mouse model and rescue experiments. Finally, we intend to verify the correlation between Tyro3/TAN/MAPK feedback loop and radioresistance of cervical cancer through large clinical samples. The successful implementation of this study will provide a new theory and a new target for reversing the radioresistance of cervical cancer.
放射治疗是宫颈癌的主要治疗方式,据统计20-40%的晚期宫颈癌患者因放疗抵抗导致治疗失败,如何在不增加放疗剂量的前提下尽可能提高宫颈癌放射敏感性是临床亟须解决的问题。课题组首先通过人类蛋白质图谱组织数据库及临床样本组织芯片发现了受体酪氨酸激酶Tyro3在宫颈癌肿瘤高表达,并在根治性放疗患者中表达越高、预后越差。同时,Tyro3高表达的肿瘤组织中弹性蛋白酶标记阳性的微环境肿瘤浸润中性粒细胞(TAN)数量较多,且两者具有正相关性。体外实验显示,放疗联用Tyro3-KD增强了其对于Hela细胞的增殖抑制作用,促进了Hela细胞的DNA损伤,但对于其DNA损伤修复无影响;放疗联用Tyro3-KD也引起了Hela细胞G2/M期阻滞及相关周期蛋白CyclinB1表达下调;共培养模型显示,Tyro3低表达的宫颈癌肿瘤细胞与中性粒细胞共培养后,其放疗抵抗性显著增加。小鼠TC-1皮下移植瘤模型显示,Tyro3的低表达显著增加了放疗敏感性、凋亡指数增加、抗凋亡蛋白表达减少,并且Tyro3高表达的宫颈癌微环境中可检测到TAN的趋化。生物信息学分析及多色免疫荧光表明Tyro3的高表达促进免疫细胞浸润,尤其与中性粒细胞表达呈正相关。进一步的机制探索确定了Tyro3通过调节PDK1-SGK1-NDRG1新通路促进CCL3分泌,引起微环境浸润中性粒细胞的趋化,诱导宫颈癌的放疗抵抗。迄今为止,有关受体酪氨酸激酶Tyro3与宫颈癌放疗抵抗的相关性,以及Tyro3介导微环境浸润中性粒细胞浸润的现象及其机制均未见报道,因此本课题具有源头创新性。本研究通过了体内外实验明确Tyro3诱导宫颈癌放疗抵抗的功能,采用共培养体系及小鼠模型、设计拯救实验阐明Tyro3与TAN介导放疗抵抗的机制,最后临床大样本验证Tyro3及TAN与宫颈癌放疗抵抗的相关性。本研究提供了逆转放疗抵抗的新思路,可为宫颈癌的放射增敏提供了新的靶点。
国内基金
海外基金